发明名称 SUBSTITUTED TETRAHYDROPYRANS AND METHOD OF USE
摘要 Compounds of formula (I);;and pharmaceutically acceptable salts or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and m are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
申请公布号 US2016122331(A1) 申请公布日期 2016.05.05
申请号 US201514926727 申请日期 2015.10.29
申请人 AbbVie Inc. 发明人 Kym Philip R.;Wang Xueqing;Searle Xenia B.;Liu Bo;Yeung Ming C.
分类号 C07D407/12;A61K45/06;A61K31/357 主分类号 C07D407/12
代理机构 代理人
主权项 1. A compound having formula (I) or a pharmaceutically acceptable salt thereof, wherein: R1 is phenyl, phenyl fused to a C3-C6cycloalkyl, or phenyl fused to a 4-6-membered heterocycle, wherein the phenyl, the phenyl of phenyl fused to a C3-C6cycloalkyl, or the phenyl of phenyl fused to a 4-6-membered heterocycle are independently optionally substituted with one, two, or three Rx groups, wherein each Rx group is independently selected, at each occurrence, from C1-C6alkyl, halogen, —CN, —NO2, —ORh, —OC(O)Ri, —OC(O)N(Rh)2, —SRh, —S(O)2Rh, —S(O)2N(Rh)2, —C(O)Ri, —C(O)ORh, —C(O)N(Rh)2, —N(Rh)2, —N(Rh)C(O)Ri, —N(Rh)S(O)2Ri, —N(Rh)C(O)O(Ri), —N(Rh)C(O)N(Rh)2, and GA, wherein the C1-C6alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of fluorine, —ORh, —OC(O)Ri, —OC(O)N(Rh)2, —SRh, —S(O)2Rh, —S(O)2N(Rh)2, —C(O)Ri, —C(O)ORh, —C(O)N(Rh)2, —N(Rh)2, —N(Rh)C(O)Ri, —N(Rh)S(O)2Ri, —N(Rh)C(O)O(Ri), —N(Rh)C(O)N(Rh)2, and -GB;wherein the C3-C6cycloalkyl of phenyl fused to a C3-C6cycloalkyl or the 4-6-membered heterocycle of phenyl fused to a 4-6-membered heterocycle are each optionally substituted with 1, 2 or 3 independently selected Rs groups; m is 0, 1, 2, or 3; Rs and Rt, at each occurrence, are each independently C1-C6alkyl, halogen, —CN, oxo, —NO2, —ORh, —OC(O)Ri, —OC(O)N(Rh)2, —SRh, —S(O)2Rh, —S(O)2N(Rh)2, —C(O)Ri, —C(O)ORh, —C(O)N(Rj)2, —N(Rh)2, —N(Rh)C(O)Ri, —N(Rh)S(O)2Ri, —N(Rh)C(O)O(Ri), —N(Rh)C(O)N(Rh)2, or GC, wherein the C1-C6alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of fluorine, —ORh, —OC(O)Ri, —OC(O)N(Rh)2, —SRh, —S(O)2Rh, —S(O)2N(Rh)2, —C(O)Ri, —C(O)ORh, —C(O)N(Rh)2, —N(Rh)2, —N(Rh)C(O)Ri, —N(Rh)S(O)2Ri, —N(Rh)C(O)O(Ri), —N(Rh)C(O)N(Rh)2, and GD; Rh, at each occurrence, is independently hydrogen, C1-C6haloalkyl, C1-C6alkyl, or GA, wherein the C1-C6alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of fluorine, —ORj, —OC(O)N(Rj)2, —SRj, —C(O)ORj, —C(O)N(Rj)2, —N(Rj)2, —CN, and GE; Ri, at each occurrence, is independently C1-C6haloalkyl, C1-C6alkyl, or GA, wherein the C1-C6alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of fluorine, —ORj, —OC(O)N(Rj)2, —SRj, —C(O)ORj, —C(O)N(Rj)2, —N(Rj)2, —CN, and GE; R2 and R3 are each independently hydrogen, C1-C6haloalkyl, or C1-C6alkyl; R4 and R5 are each independently hydrogen, C1-C6haloalkyl, C1-C6alkyl or GF, wherein the C1-C6alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of fluorine, —ORh, —OC(O)Ri, —OC(O)N(Rh)2, —SRh, —S(O)2Rh, —S(O)2N(Rh)2, —C(O)Ri, —C(O)ORh, —C(O)N(Rh)2, —N(Rh)2, —N(Rh)C(O)Ri, —N(Rh)S(O)2Ri, —N(Rh)C(O)O(Ri), and —N(Rh)C(O)N(Rh)2; or R4 and R5 together with the carbon atom to which they are attached, form a C3-C6cycloalkyl or a 4-6-membered heterocycle; wherein the C3-C6cycloalkyl and the 4-6-membered heterocycle are each optionally substituted with 1, 2, or 3 independently selected Rt groups; R6 is hydrogen, C1-C6haloalkyl, or C1-C6alkyl; R7 is an optional substituent on the cyclopropyl ring, and at each occurrence, is independently halogen, C1-C6haloalkyl, or C1-C6alkyl; R8, R9, and R10 are each independently hydrogen, halogen, —ORj, C1-C6haloalkyl, or C1-C6alkyl; R11 and R12 are each independently hydrogen, C1-C3alkyl, or halogen; GA, GB, GC, GD, GE, and GF at each occurrence, are each independently cycloalkyl, cycloalkenyl, heterocycle, aryl, or heteroaryl, each of which is independently unsubstituted or substituted with 1, 2, or 3 independently selected Ru groups; wherein Ru, at each occurrence, is independently C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, halogen, C1-C6haloalkyl, —CN, oxo, —NO2, —ORj, —OC(O)Rk, —OC(O)N(Rj)2, —SRj, —S(O)2Rj, —S(O)2N(Rj)2, —C(O)Rk, —C(O)ORj, —C(O)N(Rj)2, —N(Rj)2, —N(Rj)C(O)Rk, —N(Rj)S(O)2Rk, —N(Rj)C(O)O(Rk), —N(Rj)C(O)N(Rj)2, —(C1-C6alkylenyl)-ORj, —(C1-C6alkylenyl)-OC(O)Rk, —(C1-C6alkylenyl)-OC(O)N(Rj)2, —(C1-C6alkylenyl)-SRj, —(C1-C6alkylenyl)-S(O)2Rj, —(C1-C6alkylenyl)-S(O)2N(Rj)2, —(C1-C6alkylenyl)-C(O)Rk, —(C1-C6alkylenyl)-C(O)ORj, —(C1-C6alkylenyl)-C(O)N(Rj)2, —(C1-C6alkylenyl)-N(Rj)2, —(C1-C6alkylenyl)-N(Rj)C(O)Rk, —(C1-C6alkylenyl)-N(Rj)S(O)2Rk, —(C1-C6alkylenyl)-N(Rj)C(O)O(Rk), —(C1-C6alkylenyl)-N(Rj)C(O)N(Rj)2, or —(C1-C6alkylenyl)-CN; Rj, at each occurrence, is independently hydrogen, C1-C6alkyl, or C1-C6haloalkyl; and Rk, at each occurrence, is independently C1-C6alkyl or C1-C6haloalkyl.
地址 North Chicago IL US